RxDoctor Payments Data

Christopher Attinger

Plastic and Reconstructive Surgery · Washington, DCNPI 1710985825

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $17,810 of the $29,635 with a category attached, or 60.1%. 25 manufacturers reported payments, led by Integra Lifesciences Corporation at 54.5% of the total. Reporting peaked in 2019 at $21,151 and has fallen 95.0% since, to $1,056 in 2025.

$29,635in general payments, 2019–2025

Across 153 payments — averaging $193.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Integra Lifesciences Corporation$16K
  • KCI USA, Inc.$12K
  • Smith+Nephew$562
  • Organogenesis Inc.$211
  • Baxter Healthcare$171
  • Hydrofera LLC$135
  • plus $866 from 19 others
$79,771in research payments, 2019–2025

Across 14 payments — averaging $5697.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • KCI USA, Inc.$65K
  • Integra Lifesciences Corporation$12K
  • Bristol Myers Squibb$3K

What the payments were for

  • Consulting fees$17,81060%
  • Speaking & faculty fees$5,51319%
  • Travel & lodging$1,7266%
  • Food & beverage$3,72013%
  • Other$8673%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few plastic and reconstructive surgery providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$313,984
Medicare patients
346
Services billed
1,825

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gentamicin Sulfate27$1,236
Pregabalin31$723
Gabapentin40$643
Doxycycline Hyclate46$452
Ammonium Lactate17$285
Ciprofloxacin Hcl13$54
Tramadol Hcl11$18

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →